Understanding and Overcoming the Early Adaptive Resistance to EGFR Tyrosine-kinase Inhibitors in Lung Cancer Patients

计划入组 47 人 · 首次发布于 2020 年 1 月 9 日

Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer

计划入组 250 人 · 首次发布于 2014 年 1 月 9 日

NOV120101 Phase 2 Study in NSCLC Patients With Aquired Resistance to 1st Generation EGFR Tyrosine Kinase Inhibitors

计划入组 40 人 · 首次发布于 2012 年 10 月 31 日

EGFR tyrosine kinase inhibitors (breast cancer)

EGFR tyrosine kinase inhibitors (Anhui Normal University)

Tyrosine(Premasol, Clinimix E 2.75/5, Aminosyn-PF 7%, Primene, Clinimix 2.75/5, Trophamine 10 %, Plenamine, Olimel, Prosol, Clinisol 15, Periolimel, Travasol 10)

C₉H₁₁NO₃

Exelixis, Inc.

United States

Inhibikase Therapeutics

United States

Regeneron Pharmaceuticals

United States

EGFR-TKIs Pose Highest Cardiovascular Risk Among Tyrosine Kinase Inhibitors, Meta-Analysis Finds

Rilertinib Demonstrates Superior Survival in EGFR-Mutated NSCLC in Phase 3 Trial

Anlotinib Combined with EGFR-TKIs Shows Promise in Extending Progression-Free Survival in Advanced NSCLC